The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The company has to approach the DCGI for approval to commence the trials
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
